Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Mantle-Cell 5Lymphoma, Non-Hodgkin 4Multiple Myeloma 3Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Leukemia, B-Cell 2Waldenstrom Macroglobulinemia 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma, Follicular 1Leukemia, Prolymphocytic 1Leukemia, Hairy Cell 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1Hodgkin Disease 1Chromosome 17 deletion 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1COVID-19 1Burkitt Lymphoma 1Advanced Haematological Malignancies 1

Interventions

venetoclax 4fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 3ibrutinib 2Whole-Body Irradiation 2Tacrolimus 2Mycophenolic Acid 2Melphalan 2Dexamethasone 2pomalidomide 1pembrolizumab 1obinutuzumab 1ixazomib 1fludarabine 1dexamethasone acetate 1dexamethasone 21-phosphate 1carmustine, poliferprosan 20 drug combination 1auricularum 1acalabrutinib 1Sirolimus 1RG7388 1Nivolumab 1Etoposide 1Cytarabine 1Cyclosporins 1Cyclosporine 1Cyclophosphamide 1Carmustine 1Calcium Dobesilate 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Chromosome 17 deletion × acalabrutinib × Clear all
NCT02337829 2026-01-08

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Acerta Pharma BV

Phase 2 Completed
48 enrolled 12 charts
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡